A B S T R A C T The effect of graded doses of pentagastrin (2.7-6,000 ng/kg h) on gastric acid secretion was measured in 20 duodenal ulcer (DU) and 20 non-DU subjects. Confirming many previous studies, the mean observed highest response and the mean calculated maximal response were significantly greater in DU than in non-DU subjects. The mean dose (+SE) in ng/kg-h for half maximal response, calculated from responses corrected for basal secretion and normalized for maximal secretion, was 92.1±1.7 in DU and 246.8±24.6 in non-DU subjects, a significant difference. By parallel line bioassay non-DU subjects required 2.8 times more pentagastrin (95% confidence limits 2.1-3.7) than DU subjects for equal response expressed as percent of highest response. Thus, this study shows that, compared with non-DU subjects, DU patients not only secrete more acid in response to stimulation by pentagastrin but also are more sensitive to stimulation by pentagastrin, that is, need smaller doses to achieve the same fraction of maximal response.
increased sensitivity to stimulation, or some combination of these. Patients with DU have on the average more parietal cells than controls (7) and this is accompanied by an increased maximal capacity to secrete acid (24) . Whether, in addition to increased capacity to secrete, DU patients also have increased stimulation, increased sensitivity to stimulation, or both is uncertain.
The purpose of the present study was to compare DU and non-DU subjects in regard to responsiveness of acid secretion to stimulation by pentagastrin. Pentagastrin dose-response studies were performed. DU subjects were found to be more sensitive than non-DU subjects to stimulation of acid secretion by pentagastrin. METHODS
Pentagastrin dose response studies were performed in 20 male patients with DU disease (mean age 45, range 24-63 yr) and 20 male control subjects ( Residual juice was collected for 15 min and discarded and then basal secretion was collected for three 10-min periods. In 25 other subjects, basal secretion during the first 30 min did not differ significantly (P > 0.2) from basal secretion during the second 30 min: mean (+SE) 1.83±0.24 and 2.06+0.29 meq/30 min, respectively. Pentagastrin (tert-butoxycarbonyl-j8-alanyl-tryptophanyl-methionyl-aspartyl-phenylalaninamide, Ayerst Laboratories, New York) was then infused in graded doses of 2.7, 8.2, 25, 75, 222, 666, 2,000, and 6,000 ng/kg h. Each dose was diluted to 17 ml with 0.15 M NaCl and infused for 30 min into a forearm vein by a syringe infusion pump (Harvard Apparatus Co., Inc., Millis, Mass.). The doses were given in the order listed. The total 30-min acid output in milliequivalents was used in the analysis of the data. In separate analyses not reported here it was shown that use of the peak 10-or 20-min outputs did not alter any of the conclusions drawn from analysis of the total 30-min outputs. In previous studies in man (8) it was shown that acid secretory responses to four doses of pentagastrin each infused for 45 min did not differ significantly whether all doses were given on a single day or each dose was given on a separate day. Since any error in estimation of dose for half maximal response (D5o) that would result from giving all doses in one day would apply equally to DU and non-DU subjects, and since we felt that it would be impractical to do eight separate tests on each subj ect, we elected to conduct single-day multiple-dose testing.
Calculated maximal response (CMR) and D5o were estimated by linear regression analysis according to the equation:
(1) The least squares regression line of response/dose, x, versus response, y, gave estimates of CMR (y-intercept) and Dw (negative slope) and their standard errors. This particular linearization of the Michaelis-Menten equation was chosen because it gives the best estimates of these parameters (9) .
In dose-response studies, high basal rates can give falsely low estimates of D5o if the observed rates are used directly in the analysis. This source of error can be minimized by doing the analysis on response minus basal then calculating the basal-corrected CMR, CMRc, and the basal-corrected D5o, D50w, according to these equations (10) :
where CMRb and D5ob are CMR and D50 calculated according to Eq. 1 from values obtained by subtracting individual basal secretion rates from individual responses to each dose of pentagastrin, and B is basal rate of secretion.
In estimating CMRs and D5os the responses to the two lowest doses of pentagastrin were excluded because they were only slightly greater than basal secretion and their inclusion markedly decreased the linear correlation coefficients. Subscripts to CMR and D50 are used to indicate whether the values are derived from individual (i) data or from means (m) ; from data uncorrected (u) for basal or corrected (c) for basal; and from absolute (a) values or from values normalized (n) as a percent of highest observed response.
The statistics used in parallel line bioassays can be applied to the present problem of relative sensitivity of two groups of subjects to a single drug. In conventional bioassay a standard and an unknown drug are compared in a single population of test objects and the ratio of amount of unknown drug to amount of standard drug needed for equal responses is expressed as a potency ratio with statistically defined confidence limits. In the present case we are comparing the response of two different populations to the same drug so any difference in apparent "potency" can be interpreted as a difference in sensitivity of the two populations to the drug. "Potency" and "sensitivity" can be looked on as complementary properties, potency applying to drugs and sensitivity to test objects. In the present study, the "potency ratio" of pentagastrin was calculated by a 3+3 dose parallel line assay (11) . For this analysis the pentagastrin doses that were in the straight line portion of the log dose versus percent response curve (Fig. 4) were used: 25, 75, and 222 ng/kg h in the DU group and 75, 222, and 666 ng/kg-h in the non-DU group.
The sensitivity of individual subjects was reflected in their individual Dws. As an additional measure of individual sensitivity we used a sensitivity index calculated as the basal-corrected response to 75 ng/kg * h of pentagastrin expressed as percent of the highest observed response to pentagastrin. The correlations between these two indices of sensitivity and basal acid output and highest observed response to pentagastrin were examined.
Student's t test, Spearman's rank-order correlation coefficient, correlation coefficient, and analysis of variance were used in the statistical analysis of the data (12) . Differences were designated as significant if P <0.05.
RESULTS
Basal secretion. The mean basal acid secretion, expressed either as absolute rate (Table I) or as percent of highest observed acid secretion (Fig. 3) , was greater in DU than in non-DU subjects but the differences were not statistically significant.
Response to pentagastrin. Each dose of pentagastrin from 75 to 6,000 ng/kg h produced significantly greater mean rates of acid secretion in the DU group than in the non-DU group (Table II and Fig. 1 ) and these differences persisted after basal acid secretion was subtracted (Fig. 2) . Individual responses are included in Table  III . The greater response of DU as compared with non-DU subjects was also apparent when the responses were normalized as percent of highest observed response regardless of whether basal secretion was not (Fig. 3) or was (Fig. 4) subtracted.
Highest observed response. The highest observed response to pentagastrin was greater in DU than in non-DU subjects both when calculated as the highest mean response to any of the doses of pentagastrin used (Table II) or as the mean of the individual highest responses independent of dose of pentagastrin (Table I) . Calculated maximal response (CMR). The CMR was greater in the DU than in the non-DU group regardless of whether it was calculated from responses of individual subjects (Table I) of groups (Table IV) . The CMR calculated from mean values was greater in DU than in non-DU subjects.
Dose for half maximal response (Din). The Dso was significantly less in DU than in non-DU subjects both when calculated from responses of individual subjects (Table I) and from mean responses of groups (Table   332 J. (Table IV) .
Analysis by the 3 + 3 dose parallel line assay method.
This analysis (Table V) showed that pentagastrin was 2.82 times (confidence limits 2.12-3.74) more "potent"
in the DU group than in the non-DU group. In the context of the present study we construe differences in apparent "potency" to be attributable to differences in sensitivity. Thus this confirms by another method of analysis that DU subjects are more sensitive to stimulation by pentagastrin than non-DU subjects. Sensitivity index. The basal corrected mean response to 75 ng/kg h of pentagastrin expressed as percent of highest observed response was significantly greater in DU than in non-DU subjects (Table I) . Correlations between sensitivity and basal or maximal secretion. In neither DU nor non-DU subjects was there a significant correlation between sensitivity, as measured by the sensitivity index, and basal acid output or highest observed response to pentagastrin (Table   VI of pentagastrin in man. We cannot disprove the possibility that the dose-response curves in this study were distorted by this factor, but even if they were this would not alter the conclusions unless the degree of distortion were different in DU and non-DU subjects. Studies comparing the degree of fade in DU and non-DU subjects are needed to assess this possibility. High levels of basal secretion cause a decrease in Dso but this effect can be corrected for by subtracting basal secretion from each response (10) as was done in this study. Also, differences in peak secretory rate can affect D5o (9) . In this study the effect on D5o of differences in peak responses was minimized by normalizing the response as a percent of highest observed response to pentagastrin. The Dso for DU subjects was still significantly less than that of non-DU subjects even after these corrections for basal secretion and peak secretion had been applied.
Increased Sensitivity to Pentagastrin in Duodenal Ulcer
The correction for basal secretion (10) used in this study is based on the assumption that the drive for basal secretion has the same kinetics as the exogenous stimulant, pentagastrin in this instance. Even if the assumption is not valid, the correction could still give a valid empirical index of sensitivity. Nevertheless, an independent assessment of the influence of basal secretion on sensitivity is desirable. The finding ( Table V) that no significant correlation existed between basal secretion and sensitivity as measured by sensitivity index provides independent confirmation that differences in sensitivity between DU and non-DU groups cannot be ascribed solely to differences in basal secretion. Similarly, the lack of significant correlation between sensitivity index and highest observed response suggests that increased sensitivity is not merely another manifestation of increased capacity to secrete.
Makhlouf (16) calculated the Dso of pentagastrin by intravenous inffusion in man from six sets of data on DU and non-DU subjects in published literature and found values ranging from 60 to 300 ng/kg h. From published studies (17, 18) in which graded doses of pentagastrin were tested in DU patients we estimated the D5o to be about 55 ng/kg-h, similar to the Dw uncorrected for basal secretion of 61 ng/kg h for DU patients in the present study (Table I) .
We are aware of two previous studies comparing DU and non-DU subjects in regard to sensitivity to stimulation of acid secretion. Wormsley and Mahoney (19) reported that the response to 60 ng/kg h was 65% of the responsiveness to bolus injection of pentagastrin in DU and non-DU subjects. The Dso and CMR values obtained in DU and non-DU were quite similar. These data suggest that there are differences between different organs in relative sensitivity. However the kinetics of intravenous shots and continuous infusions may not be comparable. Recently it has been shown that continuous infusions of doses of pentagastrin sufficient to produce maximal rates of acid secretion had no effect on gastroesophageal sphincter pressure (23) . At least three hypotheses may be offered to explain increased sensitivity to pentagastrin in DU patients. First, it is known that decreasing "vagal tone" to the stomach by vagotomy (24) or by administration of atropine (25) decreases sensitivity for stimulation of gastric secretion by pentagastrin. The converse, increased "vagal tone," might then account for increased sensitivity. Unfortunately there are at present no satisfactory methods by which vagal tone can be measured. A second possibility is that circulating concentrations of inhibitors of gastrin-stimulated acid secretion, such as secretin, cholecystokinin, and other enterogastrones, are diminished in DU patients. Perfection of radioimmunoassay methods for measurement of these substances should help clarify this point. A third possibility is that the rate of disposal of pentagastrin is decreased in DU subjects. If the half-life of pentagastrin were longer in DU, circulating concentrations of pentagastrin would be higher in DU than in non-DU subjects given equal infusion rates. These higher concentrations would produce increased rates of acid secretion without a true increase in sensitivity of the parietal cell itself.
In the present study no information has been gained to support or deny any of the above three hypotheses. The data show clear evidence of a difference between DU and non-DU subjects in sensitivity to stimulation of acid secretion by pentagastrin. This increased sensitivity may play a role in the pathogenesis of duodenal ulcer disease.
